AstraZeneca Teams With Vanderbilt In Neuroscience Pact
This article was originally published in The Pink Sheet Daily
Executive Summary
Vanderbilt University’s neuroscience research group reaches its latest agreement with a pharma, this one covering compounds that treat symptoms of Alzheimer’s disease and schizophrenia by modulating a receptor in new ways.